

**CA 72.4 ( TAG-72);  
GASTRIC CANCER  
MARKER, SERUM  
(ECLIA)**

**U/mL**

**< 6.00**

**Note:** 1.This test is not recommended to screen Gastric cancer in the general population.

2. Sensitivity of monitoring Gastric carcinoma improves by combining CA 72.4 with CEA and CA 19.9 assays.

3. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy

4. This assay, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.

5. Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours after the last dose.

#### **Clinical Use**

- An aid in the management of Gastric cancer patients
- Monitor the course of disease and predict recurrence in patients with Gastric carcinoma
- Useful in detecting residual tumor

<b>DISEASE</b>	<b>PERCENTAGE POSITIVITY OF CA 72.4</b>
Gastro-intestinal carcinoma	40
Lung cancer	36
Ovarian cancer	24
Benign gastro-intestinal diseases	6.7
Healthy individuals	3.5

#### **Increased Levels**

- Gastric carcinoma
- Ovarian carcinoma

- Benign diseases – Pancreatitis, Cirrhosis, Pulmonary disease, Rheumatic conditions, Ovarian cysts, Benign breast disease, Benign gastro-intestinal disorders

Dr Lal PathLabs